We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > Psychedelics

Psychedelics

Psychedelics Sector Must Respect Indigenous Wisdoms, Say Experts

The new essay highlights numerous ethical concerns currently facing the field and emphasizes the importance of acknowledging wisdoms already known to Indigenous people.

Read More

Ketamine Can Treat Depression By Altering a Person’s Beliefs, Study Suggests

Ketamine can help people with treatment-resistant depression by breaking their entrenched belief systems, according to a recent paper.

Read More

San Francisco to Decriminalize Psychedelics

The San Francisco Board of Supervisors has unanimously voted to decriminalize psychedelics like psilocybin and ayahuasca.

Read More

Psilocybin and Ketamine Are Safer Than Xanax, Say US Psychiatrists

Most American psychiatrists view psilocybin and ketamine as safer drugs than alprazolam (Xanax), methamphetamine, or alcohol, according to a new survey.

Read More

Psychedelic Drugs Lessen Fear of Dying, Study Suggests

A psychedelic drug experience may alter people’s perspectives on death and dying in a similar way to those who have survived a near-death experience, a new study has found.

Read More

Psilocybin-Assisted Therapy Can Treat Alcohol Use Disorder, Trial Finds

The first controlled trial of psilocybin for alcohol use disorder (AUD) reports that psilocybin-assisted psychotherapy significantly reduces the occurrence of heavy drinking days in people with AUD.

Read More

Research Suggests LSD May Enhance Learning and Memory

By studying human brain organoids — tissue cultures grown from stem cells that can mimic the developing brain — researchers have found that LSD regulates numerous processes related to neuroplasticity in the human brain.

Read More

Dual Action of Ketamine May Help Limit Addiction Risk

By demonstrating that ketamine induces only a brief increase in dopamine and does not alter neuronal communication, a team from the University of Geneva suggests that its therapeutic use may be safe.

Read More

Two Novel Chemical Entitities Show Early Potential for Significant Treatment Improvement in Depression

PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic in a mouse model.

Read More

 
Advertisement